Core Viewpoint - Guizhou BaiLing's stock price has experienced a slight decline, and the company is currently involved in a legal dispute related to a financial agreement with Huachuang Securities, which may impact its financial stability and investor confidence [1] Company Overview - Guizhou BaiLing operates in the traditional Chinese medicine manufacturing industry, focusing on the research, production, and sales of苗药 (Miao medicine) [1] - The company is recognized as a key pharmaceutical enterprise in Guizhou Province, with products addressing various therapeutic areas including cold and cough, cardiovascular health, and gynecology [1] - Guizhou BaiLing holds several exclusive苗药 varieties and national protected traditional Chinese medicine varieties [1] Financial Situation - As of August 15, 2025, Guizhou BaiLing's stock price was reported at 5.99 yuan, reflecting a decrease of 0.01 yuan or 0.17% from the previous trading day [1] - The stock opened at 5.94 yuan, reached a high of 6.00 yuan, and a low of 5.72 yuan, with a trading volume of 624,746 hands and a total transaction amount of 368 million yuan [1] - On the same day, the company experienced a net outflow of main funds amounting to 56.34 million yuan, with a cumulative net outflow of 100.05 million yuan over the past five days [1] Legal and Financial Dispute - Huachuang Securities has filed a lawsuit against Guizhou BaiLing's major shareholder Jiang Wei and his associates, involving a total amount of 1.761 billion yuan [1] - The dispute originated from a financial arrangement in 2019, where Huachuang Securities provided 1.4 billion yuan in funding through two asset management plans and held an 11.54% stake in the company [1] - Additionally, Huachuang Securities extended a stock pledge loan of 361 million yuan to Jiang Wei, which has not been fulfilled as the related financial plans and pledge agreements have expired [1]

Group 1 - Huachuang Yunsin announced that its subsidiary Huachuang Securities has received court notifications regarding a restructuring plan and stock pledge dispute with Guizhou Bailing's major shareholder Jiang Wei and others [1][2] - Huachuang Securities provided a total of 1.4 billion yuan (approximately 14 billion) in funding to Jiang Wei through a restructuring plan in 2019, acquiring 161 million shares of Guizhou Bailing, representing 11.54% of its total share capital [1][2] - The restructuring plan is set to expire in July 2022 and March 2024, while the stock pledge is due in August 2024 [2] Group 2 - Huachuang Securities has filed lawsuits against Jiang Wei and others for failing to fulfill their obligations under the restructuring plan, seeking repayment of the principal amount of 1.4 billion yuan and 361 million yuan related to the stock pledge [2] - Guizhou Bailing claims to have sufficient cash flow, with its chairman Jiang Wei holding 245,346,284 shares, which is 100% pledged, representing 17.55% of the company's total share capital [2]

Core Viewpoint - Huachuang Securities, a subsidiary of Huachuang Yunxin, is involved in a legal dispute with major shareholder Jiang Wei of Guizhou Bailing Pharmaceutical Group regarding a financial rescue plan and stock pledge issues [1][2]. Group 1: Legal Proceedings - Huachuang Securities has filed lawsuits against Jiang Wei and his associates to recover 1.4 billion yuan (approximately 14 billion) from the rescue plan and 361 million yuan (approximately 3.61 billion) from stock pledge loans [2]. - The lawsuits also seek additional payments for fixed income, penalties, and other litigation-related costs [2]. Group 2: Financial Details - The rescue plan involved Huachuang Securities providing 1.4 billion yuan in funding through two asset management plans, acquiring 161 million shares of Guizhou Bailing, which represents 11.54% of the total share capital [1]. - Jiang Wei also pledged an additional 78 million shares and properties valued at approximately 1.143 billion yuan as collateral for the rescue plan [2]. - For the stock pledge loan, Jiang Wei provided additional collateral valued at approximately 263 million yuan [2]. Group 3: Company Status - Guizhou Bailing is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing [2]. - Jiang Wei is identified as the largest shareholder and actual controller of Guizhou Bailing, serving as the chairman of the company [2].

Group 1 - Huachuang Securities has filed a lawsuit against major shareholders of Guizhou Bailing, involving a total amount exceeding 1.7 billion yuan [2][5] - The dispute originated from a rescue plan initiated in 2019, where Huachuang Securities provided 1.4 billion yuan in funding in exchange for 11.54% equity in Guizhou Bailing [5] - Huachuang Securities has requested repayment of the principal amount of 1.4 billion yuan and 361 million yuan from stock pledge loans, along with associated fees and penalties [5] Group 2 - Guizhou Bailing, established in 1999, is a pharmaceutical company known for its products like Yindan Xinnaotong soft capsules and Xiaoer Chaigui antipyretic granules [6] - The company successfully removed its "ST" designation after rectifying internal control deficiencies, but it still faces an ongoing investigation by the China Securities Regulatory Commission (CSRC) for alleged information disclosure violations [6][7] - For 2024, Guizhou Bailing reported revenue of 3.825 billion yuan and a net profit of 33.62 million yuan, but its core business remains under pressure with a significant decline in performance in the first quarter [7]

Group 1 - Huachuang Securities has filed a lawsuit against major shareholders of Guizhou Bailing, involving a total amount exceeding 1.7 billion yuan [2] - The dispute originates from a rescue plan initiated in 2019, where Huachuang Securities provided 1.4 billion yuan in funding and acquired 11.54% equity in Guizhou Bailing [4] - Huachuang Securities has repeatedly urged the shareholders to fulfill their obligations, but they have failed to repay the principal and interest [4] Group 2 - Guizhou Bailing has successfully removed its "ST" designation after rectifying internal control deficiencies, but it still faces an ongoing investigation by the China Securities Regulatory Commission [6] - For the year 2024, Guizhou Bailing reported revenue of 3.825 billion yuan and a net profit of 33.62 million yuan, indicating a turnaround from previous losses [7] - Despite the recovery, the company's core business profitability remains weak, with a significant decline in performance in the first quarter of the year [7] Group 3 - As of August 14, Guizhou Bailing's stock price was 6 yuan per share, corresponding to a total market capitalization of 8.386 billion yuan [8]

Group 1 - Huachuang Securities has filed a lawsuit against major shareholders of Guizhou Bailing, involving a total amount exceeding 1.7 billion yuan [2][5] - The dispute originates from a rescue plan initiated in 2019, where Huachuang Securities provided 1.4 billion yuan in funding in exchange for an 11.54% equity stake in Guizhou Bailing [5] - Huachuang Securities has requested the courts to order the repayment of the principal amount of 1.4 billion yuan and 361 million yuan related to stock pledge loans, along with associated fees [5] Group 2 - Guizhou Bailing, established in 1999, is a pharmaceutical company known for its products such as Yindan Xinnaotong soft capsules and Xiaoer Cha Gui Tui Re granules [6] - The company faced a negative internal control audit report in 2023, leading to a temporary suspension of its stock trading, but has since rectified the issues and resumed trading [6] - For the fiscal year 2024, Guizhou Bailing reported revenues of 3.825 billion yuan and a net profit of 33.62 million yuan, although its core business still shows a loss [6][7]

Core Viewpoint - Huachuang Securities has filed a lawsuit against the major shareholder of Guizhou Bailing, involving a total amount exceeding 1.7 billion yuan due to a failure to fulfill obligations related to a financial rescue plan and stock pledge disputes [2]. Summary by Sections Legal Dispute - The dispute originates from a financial rescue plan initiated in 2019, where Huachuang Securities provided 1.4 billion yuan in funding to Jiang Wei and others in exchange for an 11.54% equity stake in Guizhou Bailing [5]. - Huachuang Securities also lent Jiang Wei 361 million yuan against a stock pledge of 110 million shares of Guizhou Bailing [5]. - The rescue plan is set to expire in July 2022 and March 2024, while the stock pledge matures in August 2024 [5]. - Despite multiple reminders from Huachuang Securities, Jiang Wei and others have not repaid the principal or provided viable solutions [5]. - The lawsuit seeks repayment of the principal amount of 1.4 billion yuan, along with fixed returns, penalties, and other related costs [5]. Company Background - Guizhou Bailing, established in 1999, is a pharmaceutical company known for its products like Yindan Xinnaotong soft capsules and Xiaoer Cha Gui Tui Re granules [7]. - The company was previously under a risk warning label due to a negative internal control audit report but has since rectified the issues and removed the warning [7]. - However, Guizhou Bailing is still under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [7]. Financial Performance - In 2024, Guizhou Bailing reported revenues of 3.825 billion yuan and a net profit attributable to shareholders of 33.62 million yuan, marking a return to profitability [8]. - Despite this, the company's net profit excluding non-recurring items remains a loss of 82.44 million yuan, indicating ongoing challenges in core business profitability [8]. - In the first quarter of the year, the company's performance declined significantly, with revenues dropping over 40% and net profits down more than 50% year-on-year [8]. Market Position - As of August 14, Guizhou Bailing's stock price was 6 yuan per share, giving it a total market capitalization of 8.386 billion yuan [9].

Group 1 - The core stock price of Guizhou Bailing as of August 7, 2025, is 6.02 yuan, with an increase of 0.02 yuan compared to the previous trading day [1] - The trading volume on that day was 950,027 hands, with a transaction amount of 578 million yuan, and a fluctuation of 5.33% [1] - Guizhou Bailing focuses on the research and production of Miao medicine, with main products covering areas such as cold and cough, cardiovascular, and gynecology [1] Group 2 - The company has a comprehensive product system for Miao medicine and continues to engage in innovative drug research and development [1] - During the morning session on August 7, the stock price experienced a rapid decline, dropping over 2% within five minutes, but later stabilized and rebounded [1] - On that day, the net inflow of main funds was 15.67 million yuan, but over the past five trading days, there has been an overall net outflow of 176 million yuan [1]

证券代码：002424 证券简称：贵州百灵 公告编号：2025-038 贵州百灵企业集团制药股份有限公司 关于注销募集资金账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 截至本公告披露日，公司募集资金专户的情况如下： | 银行名称 | 银行账户 | 账户状态 | | --- | --- | --- | | 中国工商银行股份有 | | | | | 2404032019200007439 | 本次注销 | | 限公司安顺西航支行 | | | 三、募集资金专户销户情况 鉴于上述账户募集资金已按规范要求使用完毕，募集资金专户将 不再使用。截至本公告披露日，公司已办理完成上述募集资金专户的 注销手续，公司与申万宏源证券承销保荐有限责任公司（原"宏源证 券股份有限公司"）、中国工商银行股份有限公司安顺西航支行签订的 《募集资金三方监管协议》相应终止。 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2010]629 号文核准，贵州 百灵企业集团制药股份有限公司（以下简称"公司"）向社会公开发 行人民币普通股股票 3,700 万股，每股发行价格 40.0 ...

Core Viewpoint - Guizhou Bailing stated that as of July 31, 2025, the total number of shareholders will be 85,150 [2] Summary by Category - **Company Information** - Guizhou Bailing has confirmed the total number of shareholders will reach 85,150 by July 31, 2025 [2] - **Investor Communication** - The company responded to investor inquiries on an interactive platform regarding shareholder numbers [2]